CanSino Biologics Inc. of Tianjin has introduced the world’s first needle-free, inhaled Covid-19 vaccine. This caused the company’s shares to rise as much as 14.5% on Monday morning in Hong Kong.
CanSino announced in a statement to the Hong Kong Stock Exchange that China’s National Medical Products Administration has licensed its Ad5-nCoV vaccine for use as a booster vaccine in an emergency situation.
The vaccine is a new variation of CanSino’s one-shot Covid medication, which underwent human testing for the first time around the globe in March 2020. Since its introduction in China, Mexico, Pakistan, Malaysia, and Hungary in February 2021, the vaccine has been used in those countries as well. According to CanSino, the inhaled formulation can increase protection without intramuscular injection by stimulating cellular immunity and inducing mucosal immunity.
CanSino’s initial one-shot vaccination was found to be 91% effective against severe disease and 66% effective for preventing Covid-19 symptoms, but it lags behind Sinovac Biotech Ltd. and state-owned Sinopharm Group Co. in use outside of China. The majority of the 770 million pills China has delivered to the rest of the world are distributed by those two companies.